Improving pharmacovigilance in EuropeBMJ 2010; 340 doi: https://doi.org/10.1136/bmj.c1694 (Published 12 April 2010) Cite this as: BMJ 2010;340:c1694
- Nicholas Moore, professor of pharmacology ,
- Bernard Bégaud, professor of pharmacology
- 1University of Bordeaux, Bordeaux, France
Prescribing a drug requires understanding the balance between benefits and harms.1 Knowing these requires access to information, which can come from clinical trials or pharmacovigilance. Information about clinical trials has been much improved by trial registration in a publicly accessible database, which facilitates systematic reviews and retrieval of unpublished studies, and allows patients to volunteer for these studies.2
In the linked analysis article (doi:10.1136/bmj.c1578), Garratini and colleagues,3 like others before them,4 call for further transparency so that study results and individual patient data are made public too, with of course respect for patient confidentiality. This would allow an independent reanalysis of study results,4 and the reanalysis of combined patient safety data to ensure that the risks of drugs are not greater than their benefits and that claims of efficacy are not exaggerated.3 This would apply to studies that were submitted to obtain drug registration.
Another benefit of making individual patient data publicly available is the possibility of identifying predictors of individual patient outcomes. …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial